Nevada Dental Association Endorses iCoreConnect's Cloud Software & Technology Solutions
The NDA has officially endorsed the following iCoreConnect solutions:
This endorsement highlights the NDA's commitment to empowering its members with advanced tools that improve workflow efficiency, patient care experience, and bottom-line profitability for each practice. The Nevada Dental Association joins a growing network of state dental organizations nationwide that recognize the transformative potential of iCoreConnect's technology. With over 200 product endorsements nationwide, iCoreConnect continues to set the standard as a trusted partner for dental professionals.
Robert McDermott, CEO of iCoreConnect, remarked, 'The Nevada Dental Association has long been a pillar of support for dental professionals, advocating for practice success and patient care excellence. We're honored to partner with the NDA to bring our proven cloud-based solutions to their members and help revolutionize workflows across Nevada.'
Marianna Kacyra, Executive Director of the NDA, shared her excitement: 'By endorsing iCoreConnect's innovative solutions, we're providing our members with powerful tools to streamline operations and improve patient care. The company's established success with state dental associations nationwide makes this partnership a natural fit. We're confident that iCoreConnect's solutions will deliver tremendous value to dental practices in Nevada.'
About iCoreConnect
iCoreConnect Inc. is a SaaS leader in cloud-based software and technology solutions, designed to enhance workflow productivity and profitability in healthcare.
About the Nevada Dental Association
The Nevada Dental Association is dedicated to supporting its members with services that uphold the highest standards of patient care while encouraging professional excellence and personal growth. Through education, leadership, and effective communication, the Association fosters integrity within the dental profession, strengthens doctor-patient relationships, and promotes the ADA's Principles of Ethics and Code of Professional Conduct.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing and completion of the reverse split. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors. Any forward-looking statements contained in this release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading 'Risk Factors' in the Company's Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, which are available on the SEC's website, www.sec.gov.
Investor Contacts:
888.810.7706, ext 5
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
21 minutes ago
- Miami Herald
A startup promised EV jobs to struggling towns. They're still waiting.
A startup promised 45,000 EV jobs to struggling towns. They're still waiting. They came with promises of transformation: thousands of jobs, surging salaries, and a foothold in the booming electric vehicle market. Imola Automotive USA, a Boca Raton, Florida-based startup, pitched officials in small, struggling towns in Georgia, Oklahoma, and Arkansas on a bold vision. The company planned to build six EV plants, create 45,000 jobs - and help these impoverished communities secure a place in America's green future, Floodlight reports. But over 18 months later, the company hasn't broken ground on a single site. And its top executive - whose background is in television and athletic shoes, not automotive manufacturing - has gone silent. A Floodlight investigation did not uncover lost taxpayer money in Fort Valley, Georgia; Langston, Oklahoma; or Pine Bluff, Arkansas, where Imola has sought free land, municipal financing, and other incentives for its shifting proposals. But an economic development watchdog said the episode illustrates how the frenzy to land electric vehicle jobs can leave economically distressed towns vulnerable to empty promises. Imola CEO Rodney Henry declined requests for an interview. He responded to Floodlight's inquiries with a short statement, insisting the company had not given up on its plans, which have included a partnership with an Italian manufacturer of two-seat electric vehicles. "Our timetable has been modified due to matters outside of our control," Henry said in a statement. "We are highly focused on bringing our goals into alignment. Due to proprietary consideration as well as NDA (nondisclosure) agreements, we are not at liberty to discuss specifics at this juncture." That's a stark shift from the company's earlier promises. In a press release issued in January 2024, Henry claimed the company had already secured land in multiple states to build half a dozen plants and create tens of thousands of jobs. Could someone with no experience in car manufacturing really deliver that? "It's ludicrous," said Greg LeRoy, CEO of Good Jobs First, a nonprofit that tracks and analyzes economic development projects. Building large auto plants, he said, requires "a great deal of capital, a great deal of management skill, a great deal of engineering and marketing chops. And obviously, Tesla developed those, but they didn't do it overnight, right?" Langston, Fort Valley, and Pine Bluff weren't the only towns swept up in the competition to attract electric vehicle plants. Spurred by federal policies like the Inflation Reduction Act, which unlocked billions in private investment and expanded government incentives, local officials across the country scrambled to land high-paying manufacturing jobs and a slice of the booming clean energy economy. Since the IRA passed in 2022, more than 150 EV plants have been announced in the United States, according to E2, a nonpartisan group of business leaders who advocate for economic development good for the environment. But that rush may be grinding to a halt. The recently passed "One Big Beautiful Bill," which rolls back many federal tax credits and incentives for electric vehicles, is already throwing the EV sector into turmoil - threatening to stall or shrink the kinds of ambitious projects towns like Langston, Fort Valley and Pine Bluff were counting on. E2 reports that plans for 14 EV-related plants have been canceled this year. Bold promises, then silence In three towns where Imola pledged massive investment, there's no sign of construction and little more than confusion. Langston - a town of 1,600 where more than 35% of residents live in poverty - never saw Imola's plans take shape. A 2023 letter to the city council from former Imola chief operating officer Eric Pettus stated that the company had run into "multiple obstacles," including trouble acquiring enough land. "In order for us to continue moving forward on the project, we are requesting that the City of Langston convey to us any and all vacant properties owned by the city," Pettus wrote. Langston City Council member Magnus Scott said the company also asked the town to issue municipal bonds to help them build their plant. But before any land changed hands or bonds were issued, a company representative delivered unexpected news: The deal had been canceled. "I guess maybe they ran into financial problems," Scott said. Reached by phone, Pettus, of south Florida, said he's no longer employed by Imola but instead works as a consultant for the company. Citing a nondisclosure agreement, he declined to discuss Imola's plans. Fort Valley gave its backing in early 2024 to Imola's ambitious plan to build an EV plant that would employ 7,500 workers. A year later, with no sign of progress on the plant, the company came back to the Georgia town with an entirely different proposal. This time, instead of building an EV plant, they pitched a high-tech lighting system for the town. One city council member balked. "You want us to sign an agreement for 99 years before you bring us the car company," said council member Laronda Eason, according to minutes of the March 2025 meeting. "It feels like a bait and switch." Eason did not respond to emails and text messages seeking comment on the Imola proposal. In Pine Bluff, where per capita income last year was just over $21,000, city officials were initially all in. Writing to Henry in August 2024, then-Mayor Shirley Washington said the city of 39,000 stood ready to buy land, build infrastructure, and issue industrial revenue bonds to support Imola's vision. "With an anticipated employment base of more than 8,000 jobs," Washington wrote, "we firmly believe this investment will marshal a pivotal turning point in our community." But a year later, the project hasn't moved. "We never did get off the ground with that," Washington said in a brief phone interview. LeRoy said Imola's pitch fits a troubling pattern. "It grabs me as an example of how the craze among governors and mayors to get the next big thing has caused some sloppy vetting," he said of the struggling communities courted by Imola. Such towns, he said, are "easy prey. …They're desperate." Grand vision, missing details Henry, who lives in Florida, touts a background as a longtime TV executive producer and the founder of Protégé, an athletic footwear brand. He claims on his IMDB profile that Protégé donated a million pairs of shoes to African nations. But despite announcements of partnerships and promises of good-paying jobs, his EV company has yet to show any tangible progress. Floodlight found the website for Imola - named after the Italian city where Tazzari EVs are made - is no longer accessible without a password. A search of the Tazzari website found no mention of plants in the United States. But a 2024 version of the Imola site mentions the tiny vehicles "coming soon to America." In early 2024, Imola Automotive USA and the Tazzari Group - an Italian firm best known for its electric two-seater micro cars - jointly announced plans for a partnership. The EVs that Tazzari makes in Italy aren't designed for highway driving. Top speed on the company's Opensky Sport model is about 56 miles per hour, while maximum speed on the Opensky Limited is about 37 mph, according to the company's webpage. Tazzari didn't respond to email messages from a Floodlight reporter. Henry said at that time that the company chose Langston and Fort Valley because of their universities. "Both of these locations are ideal," he said in the January 2024 news release, "as their proximity to communities with institutions of higher learning, will allow residents and students career opportunities in the fast growing EV Technology and Innovation Industry." Many local officials in Fort Valley, Langston and Pine Bluff did not respond to interview requests. Few documents were provided in response to Floodlight's public records requests. But it's clear from available records that Imola's promises stirred hope. Langston Mayor Michael Boyles called the proposal "transformative" in a January 2024 news release. But some local leaders soon began to question the details. Erica Johnson, a real estate agent and former member of Langston's economic development commission, said parts of the plan didn't add up. How, for instance, would the company house more than 1,000 workers in such a small town? And how were they going to build such a large plant on land without utilities or water? Her doubts deepened when she learned that Imola wanted to lock down land agreements without putting up any earnest money. "My early feeling was that, 'Something is not quite okay with this,' " she said. "But I think the hope for our community kind of outweighed the ability to just take things slow and look at them for where they are and what they are - versus where you hope them to be." Eventually, the promise fizzled. "It was disappointing," Johnson said. "...We could have had our energy and time focused on something that seemed more valid and more substantial." Still waiting for the shovels Some residents in Fort Valley are still holding out hope. Mayor Jeffery Lundy said early last year that it was a "priority for my administration to land a company like Imola Automotive USA." Local officials, he said, were looking forward to the economic boost the plant would bring. At the time, Imola claimed it would break ground on a 195-acre site by the third quarter of 2024 and open the plant within 20 months, according to a report in the Macon Telegraph. During a February 2024 town hall meeting, Imola officials told residents that the plant would pay employees an average of $45 an hour, according to a Facebook post. Commenters buzzed with excitement, with one writing: "Application me !!!!" Pettus told a local TV station that most jobs would require only a high school diploma. In early 2024, Fort Valley rezoned land to accommodate the plant, and the city council signed off on the deal. But more than 15 months later, there's still no sign of construction. Council members were told that Georgia Power couldn't provide sufficient power for the EV company, according to minutes of their March 2025 meeting. A spokesman for Georgia Power said that while the utility doesn't discuss economic development projects, "We're prepared and ready to meet the energy needs of any new customer." Makita Driver, one of the Facebook commenters who'd voiced excitement about the proposed EV plant, said there's no doubt she would have applied for one of the jobs there - had the facility ever been built. "The pay rate was really what got my attention," she said. As a medical assistant, Driver said she earns far less than what Imola had promised. But she eventually concluded the promises were too good to be true. "Who really makes that kind of money starting out?" she asked. In a brief interview with Floodlight on July 11, Mayor Lundy said he's still in contact with Henry. "We are patiently waiting for that groundbreaking," Lundy said. Floodlight is a nonprofit newsroom that investigates the powers stalling climate action. This story was produced by Floodlight and reviewed and distributed by Stacker. © Stacker Media, LLC.
Bloomberg
29 minutes ago
- Bloomberg
Open Interest 8/20/2025
Get a jump start on the US trading day with Matt Miller and Katie Greifeld on "Bloomberg Open Interest." Target is naming long-time insider Michael Fiddelke as its next chief executive officer. He'll be tasked with turning around the struggling retailer. And Lowe's makes a $8.8B deal that will help the home improvement retailer cater to more professional customers. And tech troubles mount as Nasdaq struggles to recover from it's second biggest 1-day drop since April's tariff shock. And what does it cost to fire a CEO? Bloomberg Big Take crunched the numbers after the high-profile ousters at Nike and Starbucks. (Source: Bloomberg)
Yahoo
37 minutes ago
- Yahoo
Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.
FDA-approved antibiotic with the power of a penem in a novel oral formulation, offering a vital alternative in treating uncomplicated urinary tract infections DUBLIN and CHICAGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the U.S. commercial launch of ORLYNVAH™ (sulopenem etzadroxil and probenecid) oral tablets. The Food and Drug Administration (FDA) approved ORLYNVAH™ for adult women with uncomplicated urinary tract infections (uUTIs) caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis with limited or no alternative oral antibacterial options in October 2024. ORLYNVAH™ is the first oral penem antibiotic commercially available in the U.S. and the first new branded product to be introduced in the U.S. for uUTI in more than 25 years – offering a critical option for patients and physicians facing a shrinking arsenal of effective oral therapies. Sixty percent of women experience a urinary tract infection in their lifetime and 44% experience three or more episodes annually. It is the most common outpatient infection in women in the United States, and resistance continues to increase. According to a 2024 U.S. study in approximately 150,000 patients with uncomplicated UTIs: 57% of initial infections were resistant to at least one antibiotic class; and 13% were resistant to three or more. Without new, safe and effective oral therapies, resistant uUTIs are expected to inflate healthcare costs and may lead to poor patient outcomes in the U.S., including the need for additional courses of therapy, emergency room visits or hospitalizations, all of which underscore the urgent need for innovation in this space. 'The availability of ORLYNVAH™ is tremendous news for clinicians and patients alike,' said Marjorie Golden, MD, FIDSA, Site Chief, Infectious Disease, St. Raphael Campus Yale New Haven Hospital. 'The launch of ORLYNVAH™ provides a new treatment option with impressive efficacy data to treat appropriate adult women suffering from difficult-to-treat uUTIs.' Dr. Golden added, 'For patients who currently have limited treatment options, ORLYNVAH™ provides a long overdue oral alternative that allows for treatment in the community. This paradigm shift in the management of patients with uUTI will not only reduce emergency department visits and hospital admissions, but it will also favorably impact patients' quality of life.' 'Our mission is to create new antibiotics for patients and to be a treatment alternative to address substantial unmet medical needs in the community,' said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. 'For many people with multidrug-resistant uUTIs, options have been exhausted. We're proud to introduce ORLYNVAH™—the first oral penem ever approved by the FDA—giving clinicians and patients a much-needed new therapy.' To support patient access, Iterum Therapeutics is launching a copay savings program allowing eligible patients to obtain ORLYNVAH™ for as little as $25. For more information about ORLYNVAH™, including full prescribing information, please visit Uncomplicated urinary tract infections (uUTIs) are a common bladder infection typically confined to the lower urinary tract in otherwise healthy women with no structural abnormalities of the urinary tract—caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis. About Iterum Therapeutics plcIterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug-resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received U.S. Food and Drug Administration approval for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs) caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options, and ORLYNVAH™ is commercially available in the United States. Iterum has also been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit About ORLYNVAH™ORLYNVAH™ is a novel oral penem antibiotic for the treatment of uUTIs. ORLYNVAH™ possesses potent activity against species of Enterobacterales including those that encode ESBL or AmpC-type ß-lactamases that confer resistance to third generation cephalosporins. Cautionary Note Regarding Forward-looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding Iterum's plans, strategies and prospects for its business, including the development, therapeutic and market potential of ORLYNVAH™ and the success of Iterum's commercialization of ORLYNVAH™ in the U.S. In some cases, forward-looking statements can be identified by words such as 'may,' 'believes,' 'intends,' 'seeks,' 'anticipates,' 'plans,' 'estimates,' 'expects,' 'should,' 'assumes,' 'continues,' 'could,' 'would,' 'will,' 'future,' 'potential' or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Iterum's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may be materially different from what is expected due to factors largely outside Iterum's control, including Iterum's successful commercialization of ORLYNVAH™ in the U.S. with its commercial partner, EVERSANA, including Iterum's ability to maintain and continue to build a sales force for the commercialization of ORLYNVAH™ in the U.S., the ability of shareholders and other stakeholders to realize any value or recovery as part of a wind down process if the commercialization of ORLYNVAH™ in the U.S. is unsuccessful, the market opportunity for and the potential market acceptance of ORLYNVAH™ for uUTIs caused by certain designated microorganisms in adult women who have limited or no alternative oral antibacterial treatment options, the potential impact of resistant uUTIs on healthcare costs and medical outcomes for uUTI patients in the U.S., Iterum's ability to continue as a going concern, uncertainties inherent in the conduct of clinical and non-clinical development, changes in regulatory requirements or decisions of regulatory authorities, the timing or likelihood of regulatory filings and approvals, changes in public policy or legislation, the actions of third-party clinical research organizations, suppliers and manufacturers, the accuracy of Iterum's expectations regarding how far into the future Iterum's cash on hand will fund Iterum's ongoing operations, Iterum's ability to maintain its listing on the Nasdaq Capital Market and other factors discussed under the caption 'Risk Factors' in its Quarterly Report on Form 10-Q filed with the SEC on August 5, 2025, and other documents filed with the SEC from time to time. Forward-looking statements represent Iterum's beliefs and assumptions only as of the date of this press release. Except as required by law, Iterum assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. PRESS CONTACTJennifer PerciballiOak+Cannon PR for Iterumjennifer@ Investor RelationsJudy MatthewsChief Financial Officer Iterum Therapeutics 312-778-6073IR@
